Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The company has received approval from DCGI to begin patient enrolment and dosing in the country
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
_256_384.jpg)
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Subscribe To Our Newsletter & Stay Updated
